Regulation of Degradative Pathways in Tauopathies
Regulation of Degradative Pathways in Tauopathies
批准号:
10016387
负责人:
Clarissa Valdez
金额:
$7.47万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-28 至 2023-08-31
关键词:
3-DimensionalAffectAgingAlzheimer&aposs DiseaseAmericanAreaAstrocytesAtherosclerosisBiological AssayBrainCTSD geneCathepsinsCleaved cellCoculture TechniquesDegradation PathwayDementiaDiseaseDoctor of PhilosophyDoseEnzymesFrontotemporal Lobar DegenerationsFunctional disorderGenerationsGoalsHumanImpaired cognitionImpairmentIn VitroIndividualLaboratoriesLeadLearningLinkMalignant NeoplasmsMentorsMicrogliaModelingMutationNerve DegenerationNeurodegenerative DisordersNeurogliaNeuronal Ceroid-LipofuscinosisNeuronsNeurosciencesOligodendrogliaPGRN genePathogenesisPathogenicityPathway interactionsPatientsPhenotypePopulationPositioning AttributePostdoctoral FellowProcessProtein PrecursorsProteinsProteolysisRecombinantsRegulationResearchResearch PersonnelRoleScientistSocietiesStudy modelsSystemTauopathiesTechniquesTestingTherapeuticTimeTrainingTranslational ResearchUbiquitinWorkWritingbasebehavioral impairmentcarboxypeptidase Ccareercombatdoctoral studentexperiencegranulinin vitro activityinduced pluripotent stem cellinsightinterestmutantneurodegenerative phenotypenovelpost-doctoral trainingprotein TDP-43skillssocioeconomics
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Frontotemporal lobar degeneration (FTLD) encompasses a group of neurodegenerative disorders
characterized by cognitive and behavioral impairments. Heterozygous mutations in progranulin (PGRN) result
in decreased PGRN expression and account for ~25% of familial FTLD. In contrast, homozygous PGRN
mutations result in complete loss of PGRN and lead to neuronal ceroid lipofuscinosis (NCL), a group of
neurodegenerative lysosomal storage disorders. Thus, PGRN mutations appear to cause different diseases
(FTLD vs NCL) in a dose-dependent manner, suggesting that heterozygous PGRN mutations might cause
FTLD via partial loss of lysosomal function. My PhD Dissertation Project aims to determine if reduced PGRN
expression, due to FTLD-linked PGRN heterozygous mutations, causes lysosomal dysfunction and contributes
to neurodegeneration in FTLD. Using iPSC-derived human cortical neurons derived from FTLD patients
harboring PGRN mutations compared to isogenic controls, we have demonstrated that PGRN mutant neurons
have significantly impaired lysosomal proteolysis. To determine the mechanism of this impaired lysosomal
proteolysis, we examined the relationship between PGRN and the lysosomal enzyme cathepsin D. Mutations
in PGRN and CTSD both lead to similar forms of NCL, and cathepsin D is predominantly expressed in the
brain where it is responsible for the degradation of long-lived proteins. We found that cathepsin D activity, but
not its expression was significantly decreased in PGRN mutant neurons. Furthermore, we demonstrated that
PGRN interacts with cathepsin D, and that granulins, cleavage products of PGRN, significantly increase
cathepsin D activity in vitro. Based upon these initial results, we propose a novel role for PGRN in regulating
lysosomal cathepsin D activity, which is disrupted by loss of PGRN expression in FTLD-linked heterozygous
mutant neurons, leading to defective lysosomal function in FTLD. To further investigate these results, we will
perform in vitro dose-dependent cathepsin D activity curves using recombinant granulins to determine if
individual granulins cleaved from PGRN specifically regulate cathepsin D activity. Furthermore, we will
determine if PGRN interacts with or alters the activity of other lysosomal enzymes in addition to cathepsin D.
Finally, we will use long-term cultures of FTLD patient-derived PGRN mutant iPSC cortical neurons to
determine if lysosomal dysfunction resulting from decreased cathepsin D activity contributes to pathogenic
FTLD hallmarks such as ubiquitin and TDP-43 positive inclusion formation. This PhD Dissertation Project will
provide important insight into both the normal role of PGRN in regulating lysosomal function and the cellular
mechanisms by which PGRN mutations cause FTLD in human neurons. As a Postdoctoral trainee, I will
expand upon my PhD training by studying how glial cells contribute to neurodegenerative phenotypes.
Ultimately, I plan to merge my PhD and postdoctoral training by becoming an academic researcher
investigating the role of neuronal-glial interactions in the pathogenesis of neurodegeneration.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Regulation of Degradative Pathways in Tauopathies
-
批准号:10241433
-
项目类别:
-
资助金额:$7.47万
-
财政年份:2017
-
负责人:Clarissa Valdez
-
依托单位:
Regulation of Degradative Pathways in Tauopathies
-
批准号:9921634
-
项目类别:
-
资助金额:$7.47万
-
财政年份:2017
-
负责人:Clarissa Valdez
-
依托单位:
海外基金